Her primary areas of study are Internal medicine, Oncology, Cancer, Adenocarcinoma and Pancreatic cancer. Her research in Internal medicine intersects with topics in Gastroenterology and Germline mutation. Her study in Oncology is interdisciplinary in nature, drawing from both Gemcitabine, Clinical endpoint, Cetuximab and DNA mismatch repair.
Her Cancer research is multidisciplinary, incorporating perspectives in Proteome, Cancer research, Proteomics and Pathology. Her work deals with themes such as Carcinoma and Deep sequencing, which intersect with Adenocarcinoma. Her Pancreatic cancer study combines topics in areas such as Pancreatectomy, Clinical trial and Radiation therapy.
Internal medicine, Oncology, Pancreatic cancer, Cancer and Gemcitabine are her primary areas of study. The Internal medicine study combines topics in areas such as Gastroenterology and Surgery. Her Oncology study which covers Germline that intersects with Olaparib and PALB2.
Her Pancreatic cancer research is multidisciplinary, incorporating elements of Cancer research, Bioinformatics, Survival rate, Adjuvant and Radiation therapy. She combines subjects such as Pancreas, Cohort, Pathology, General surgery and Hazard ratio with her study of Cancer. Her studies in Gemcitabine integrate themes in fields like Clinical endpoint, Cisplatin, FOLFIRINOX and Performance status.
Eileen M. O'Reilly mostly deals with Internal medicine, Oncology, Cancer, Pancreatic cancer and Germline. Her work is connected to Hazard ratio, Gemcitabine, Colorectal cancer, Clinical endpoint and Randomized controlled trial, as a part of Internal medicine. Her Gemcitabine study integrates concerns from other disciplines, such as Gastroenterology and Adjuvant.
Her Oncology research integrates issues from Young adult, Metastatic pancreatic cancer, Germline mutation and Clinical trial. Eileen M. O'Reilly has researched Cancer in several fields, including Radiation therapy and Pancreas. Her Germline study integrates concerns from other disciplines, such as Olaparib and PALB2.
Her scientific interests lie mostly in Internal medicine, Oncology, Cancer, Pancreatic cancer and Germline. Her Internal medicine study combines topics in areas such as Gastroenterology and Gene. Eileen M. O'Reilly interconnects Germline mutation, Borderline resectable, Pancreas and Clinical trial in the investigation of issues within Oncology.
Her work deals with themes such as Proteome and Proteomics, which intersect with Cancer. Her Pancreatic cancer research includes themes of Chromatin, Gene expression profiling, Bone marrow and Somatic evolution in cancer. Her research investigates the connection with Germline and areas like PALB2 which intersect with concerns in BAP1.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan;Pascal Hammel;Michele Reni;Eric Van Cutsem.
The New England Journal of Medicine (2019)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler;Donna Niedzwiecki;Donna Hollis;Susan Sutherland.
Journal of Clinical Oncology (2010)
Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology
Margaret A. Tempero;Mokenge P. Malafa;Mahmoud Al-Hawary;Horacio Asbun.
Journal of The National Comprehensive Cancer Network (2017)
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
Philip A. Philip;Jacqueline Benedetti;Christopher L. Corless;Ralph Wong.
Journal of Clinical Oncology (2010)
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.
Itaru Endo;Mithat Gonen;Adam C. Yopp;Kimberly M. Dalal.
Annals of Surgery (2008)
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial
Alan P. Venook;Donna Niedzwiecki;Heinz Josef Lenz;Federico Innocenti.
Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Manish A. Shah;Ramesh K. Ramanathan;David H. Ilson;Alissa Levnor.
Journal of Clinical Oncology (2006)
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
A. Duffy;M. Capanu;G.K. Abou-Alfa;D. Huitzil.
Journal of Surgical Oncology (2008)
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma
Joseph M. Herman;Daniel T. Chang;Karyn A. Goodman;Avani S. Dholakia.
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
Ayuko Hoshino;Ayuko Hoshino;Han Sang Kim;Han Sang Kim;Linda Bojmar;Linda Bojmar;Linda Bojmar;Kofi Ennu Gyan.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: